Created at	Source	Raw Value	Validated value
Feb. 18, 2022, 5 p.m.	usa	Cohort 1: HIV- Participants with Solicited Adverse Events (AEs);Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 1: HIV- Participants with Unsolicited AEs;Cohort 2: HIV+ Participants with Solicited AEs;Cohort 2: HIV + Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 2: HIV+ Participants with Unsolicited AEs;Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs);Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs);Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs);Healthcare Worker Expansion (Cohort 3): Participants with AESI's;Healthcare Worker Expansion (Cohort 4): Participants with AESI's	Cohort 1: HIV- Participants with Solicited Adverse Events (AEs);Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 1: HIV- Participants with Unsolicited AEs;Cohort 2: HIV+ Participants with Solicited AEs;Cohort 2: HIV + Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 2: HIV+ Participants with Unsolicited AEs;Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs);Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs);Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs);Healthcare Worker Expansion (Cohort 3): Participants with AESI's;Healthcare Worker Expansion (Cohort 4): Participants with AESI's
Oct. 26, 2020, 11:31 p.m.	usa	Cohort 2: HIV+ Participants with Solicited AEs;Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs);Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 1: HIV- Participants with Symptomatic Moderate or Severe COVID-19;Cohort 1: HIV- Participants with Solicited Adverse Events (AEs);Cohort 1: HIV- Participants with Unsolicited AEs;Cohort 2: HIV+ Participants with Unsolicited AEs;Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs);Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)	Cohort 2: HIV+ Participants with Solicited AEs;Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs);Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19;Cohort 1: HIV- Participants with Symptomatic Moderate or Severe COVID-19;Cohort 1: HIV- Participants with Solicited Adverse Events (AEs);Cohort 1: HIV- Participants with Unsolicited AEs;Cohort 2: HIV+ Participants with Unsolicited AEs;Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs);Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)